Development of a chimeric plasmodium berghei strain expressing the repeat region of the p. vivax circumsporozoite protein for in vivo evaluation of vaccine efficacy

Infection and Immunity

Volumn 81, Issue 8, 2013, Pages 2882-2887

  Espinosa, Diego A ^a   Yadava, Anjali ^b   Angov, Evelina ^b   Maurizio, Paul L ^a   Ockenhouse, Christian F ^b   Zavala, Fidel ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; MALARIA VACCINE; MONOCLONAL ANTIBODY; PARASITE ANTIBODY; POLYCLONAL ANTIBODY;

ANTIBODY RESPONSE; ARTICLE; IMMUNE RESPONSE; IN VIVO STUDY; PLASMODIUM BERGHEI; PLASMODIUM VIVAX; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CHIMERA; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; MALARIA VACCINES; MICE; PLASMODIUM BERGHEI; PLASMODIUM VIVAX; PROTOZOAN PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 84880653698     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00461-13     Document Type: Article

References (37)

1. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. 2007. Vivax malaria: neglected and not benign. Am. J. Trop. Med. Hyg. 77:79-87.
2. Gething PW, Elyazar IRF, Moyes CM, Smith DL, Battle KE, Guerra CA, Patil AP, Tatem AJ, Howes RE, Myers MF, George DB, Horby P, Wertheim HFL, Price RN, Mueller I, Baird JK, Hay SI. 2012. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl. Trop. Dis. 6:e1814. doi: 10.1371/journal.pntd.0001814.
3. Arévalo-Herrera M, Chitnis C, Herrera S. 2010. Current status of Plas-modium vivax vaccine. Hum. Vaccin. 6:124-132.
4. Mendis K, Sina BJ, Marchesini P, Carter R. 2001. The neglected burden of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 64:97-106.
5. Baird JK. 2007. Neglect of Plasmodium vivax. Trends Parasitol. 23:533-539.
6. Baird JK. 2013. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin. Microbiol. Rev. 26:36-57.
7. Carlton JM, Sina BJ, Adams JH. 2011. Why is Plasmodium vivax a neglected tropical disease? PLoS Negl. Trop. Dis. 5:e1160. doi: 10.1371/journal.pntd.000160.
8. Pigott DM, Atun R, Moyes CL, Hay SI, Gething PW. 2012. Funding for malaria control 2006-2010: a comprehensive global assessment. Malar. J. 11:246.
9. Battle KE, Gething PW, Elyazar IR, Moyes CL, Sinka ME, Howes RE, Guerra CA, Price RN, Baird KJ, Hay SI. 2012. The global public health significance of Plasmodium vivax. Adv. Parasitol. 80:1-111.
10. Herrera S, Corradin G, Arévalo-Herrera M. 2007. An update on the search for a Plasmodium vivax vaccine. Trends Parasitol. 23:122-128.
11. Tam JP, Clavijo P, Lu YA, Nussenzweig V, Nussenzweig R, Zavala F. 1990. Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria. J. Exp. Med. 171:299-306.
12. Zavala F, Tam JP, Romero PJ, Ley V, Nussenzweig RS, Nussenzweig V. 1987. Synthetic peptide vaccine confers protection against murine malaria. J. Exp. Med. 66:1591-1596.
13. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, Schwenk R, Nielsen RA, Debebe Z, Pinelis E, Juompan L, Williams J, Dowler M, Stewart VA, Wirtz RA, Dubois MC, Lievens M, Cohen J, Ballou WR, Heppner DG, Jr, RTS, S. Vaccine Evaluation Group. 2009. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S/AS01B and RTS, S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J. Infect. Dis. 200:337-346.
14. Persson C, Oliveira GA, Sultan AA, Bhanot P, Nussenzweig V, Nardin EH. 2002. Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falcipa-rum circumsporozoite protein. J. Immunol. 169:6681-6685.
15. Romero P, Heimer EP, Herrera S, Felix AM, Nussenzweig RS, Zavala F. 1987. Antigenic analysis of the repeat domain of the circumsporozoite protein of Plasmodium vivax. J. Immunol. 139:1679-1682.
16. Yadava A, Sattabongkot J, Washington MA, Ware LA, Majam V, Zheng H, Kumar S, Ockenhouse CF. 2007. A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites. Infect. Immun. 75:1177-1185.
17. Wang Q, Fujioka H, Nussenzweig V. 2005. Exit of Plasmodium sporo-zoites from oocysts is an active process that involves the circumsporozoite protein. PLoS Pathog. 1:e9. doi :10.1371/journal.ppat.0010009.
18. Cockburn IA, Tse S-W, Radtke AJ, Srinivasan P, Chen Sinnis Y-CP, Zavala F. 2011. Dendritic cells and hepatocytes use distinct pathways to process protective antigen from Plasmodium in vivo. PLoS Pathog. 7:e1001318. doi:10.1371/journal.ppat.1001318.
19. Angov E, Hillier CJ, Kincaid RL, Lyon JA. 2008. Heterologous protein expressionisenhanced byharmonizing the codon usage frequencies ofthe target gene with those of the expression host. PLoS One 3:e2189. doi: 10.1371/journal.pone.0002189.
20. Janse CJ, Ramesar J, Waters AP. 2006. High-efficiency transfection and drug selection of genetically transformed blood stages of the rodent malaria parasite Plasmodium berghei. Nat. Protoc. 1:346-356.
21. Menard R, Janse CJ. 1997. Gene targeting in malaria parasites. Methods 13:148-157.
22. Bruñ-Romero O, Hafalla JC, González-Aseguinolaza G, Sano G, Tsuji M, Zavala F. 2001. Detection of malaria liver-stages in mice infected through the bite of a single Anopheles mosquito using a highly sensitive real-time PCR. Int. J. Parasitol. 31:1499-1502.
23. Yoshida N, Nussenzweig RS, Potocnjak P, Nussenzweig V, Aikawa M. 1980. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science 207:71-73.
24. Nardin EH, Nussenzweig V, Nussenzweig RS, Collins WE, Harinasuta KT, Tapchaisri P, Chomcharn Y. 1982. Circumsporozoite protein of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J. Exp. Med. 156:20-30.
25. Zavala F, Cochrane AH, Nardin EH, Nussenzweig RS, Nussenzweig V. 1983. Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes. J. Exp. Med. 157:1947-1957.
26. Cao Y, Zhang D, Pan W. 2009. Construction of transgenic Plasmodium berghei as a model for evaluation of blood-stage vaccine candidate of Plasmodium falciparum chimeric protein 2.9. PLoS One 4:e6894. doi:10.1371/journal.pone.0006894.
27. de Koning-Ward TF, O'Donnell RA, Drew DR, Thomson R, Speed TP, Crabb BS. 2003. A new rodent model to assess blood stage immunity to the Plasmodium falciparum antigen merozoite surface protein 119 reveals a protective role for invasion inhibitory antibodies. J. Exp. Med. 198:869-875.
28. Mlambo G, Maciel J, Kumar N. 2008. Murine model for assessment of Plasmodium falciparum transmission-blocking vaccine using transgenic Plasmodium berghei parasites expressing the target antigen Pfs25. Infect. Immun. 76:2018-2024.
29. Ramjanee S, Robertson JS, Franke-Fayard B, Sinha R, Waters AP, Janse CJ, Wu Y, Blagborough AM, Saul A, Sinden RE. 2007. The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials. Vaccine 25:886-894.
30. Amino R, Thiberge S, Martin B, Celli S, Shorte S, Frischknecht F, Menard R. 2006. Quantitative imaging of Plasmodium transmission from mosquito to mammal. Nat. Med. 12:220-224.
31. Tewari K, Spaccapelo R, Bistoni F, Holder AA, Crisanti A. 2002. Function of region I and II adhesive motifs of Plasmodium falciparum circumsporozoite protein in sporozoite motility and infectivity. J. Biol. Chem. 277:47613-47618.
32. Nardin EH, Oliveira GA, Calvo-Calle JM, Wetzel K, Maier C, Birkett AJ, Sarpotdar P, Corado ML, Thornton GB, Schmidt A. 2004. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect. Immun. 72:6519-6527.
33. Calvo-Calle JM, Oliveira GA, Watta CO, Soverow J, Parra-Lopez C, Nardin EH. 2006. A linear peptide containing minimal T- and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge. Infect. Immun. 74:6929-6939.
34. Oliveira GA, Wetzel K, Calvo-Calle JM, Nussenzweig R, Schmidt A, Birkett A, Dubovsky F, Tierney E, Gleiter CH, Boehmer G, Luty AJ, Ramharter M, Thornton GB, Kremsner PG, Nardin EH. 2005. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect. Immun. 73:3587-3597.
35. Kumar KA, Oliveira GA, Edelman R, Nardin EH, Nussenzweig V. 2004. Quantitative Plasmodium sporozoite neutralization assay (TSNA). J. Immunol. Methods 292:157-164.
36. Palma C, Overstreet MG, Guedon JM, Hoiczyk E, Ward C, Karen KA, Zavala F, Ketner G. 2011. Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in mice. Vaccine 29:1683-1689.
37. Kastenmüller K, Espinosa DA, Trager L, Stoyanov C, Salazar AM, Pokalwar S, Singh S, Dutta S, Ockenhouse CF, Zavala F, Seder RA. 2013. Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I-C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mice. Infect. Immun. 81:789-800.